18:20 , Oct 18, 2018 |  BC Innovations  |  Distillery Techniques

Assays and screens

TECHNOLOGY: Diagnostic assays A VAR2CSA-coated magnetic bead-based method for detecting circulating tumor cells (CTCs) could help diagnose prostate cancer and the stage of disease. The method consists of introducing plasma samples from patients and magnetic...
21:28 , Aug 20, 2018 |  BC Extra  |  Preclinical News

Malaria protein helps detect circulating tumor cells

VarCT Diagnostics ApS is developing a cancer diagnostic that employs a malaria protein to target circulating tumor cells based on research from University of Copenhagen and colleagues. The academic team previously showed that the recombinant...
07:00 , May 19, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Chondroitin sulfate proteoglycans (CSPG); versican (VCAN)

Autoimmune disease INDICATION: Multiple sclerosis (MS) In vitro and mouse studies identified a UDP-N-acetylglucosamine-based inhibitor of CSPG synthesis that could help treat MS. Chemical synthesis of UDP-N-acetylglucosamine analogs and testing in mouse and human astrocyte-based...
08:00 , Dec 17, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Variant surface antigen 2 chondroitin sulphate A (VAR2CSA); chondroitin sulfate proteoglycans (CSPG)

Cancer INDICATION: Cancer Patient sample, cell culture and mouse studies suggest VAR2CSA conjugated to cytotoxic agents could help treat cancer. In patients with various types of epithelial cancers, bone sarcomas or soft tissue sarcomas, binding...
07:00 , May 1, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Spinal cord injury (SCI) Chondroitin sulfate proteoglycan (CSPG) Rat studies suggest lentivirus-delivered, mammalian-optimized chondroitinase ABC (ChABC) could help treat SCI. Levels of extracellular matrix-associated CSPGs...
08:00 , Mar 6, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Spinal cord injury (SCI) Neurotrophic tyrosine kinase receptor 2 (NTRK2; TrkB); NTRK3 (TrkC); chondroitin sulfate proteoglycan (CSPG) Studies in rats suggest engineered Schwann cells could...
07:00 , Mar 22, 2012 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Nerve damage Chondroitin sulfate proteoglycan (CSPG); chondroitin sulphate E (CS-E) In vitro and mouse studies suggest inhibiting the CSPG disaccharide subunit CS-E could help treat...
07:00 , Oct 27, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Spinal cord injury (SCI) Protein tyrosine phosphatase receptor type F (PTPRF; LAR) Rodent studies suggest blocking the interaction between LAR and chondroitin sulfate proteoglycans (CSPGs)...
07:00 , Jul 28, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Spinal cord injury (SCI) Chondroitin sulfate proteoglycan (CSPG) Rat studies suggest a peripheral nerve autograft plus treatment to dissolve CSPGs could improve recovery following SCI....
07:00 , Jul 1, 2010 |  BC Innovations  |  Targets & Mechanisms

Neuraminidase for spinal cord injury

Researchers at The Johns Hopkins University School of Medicine have shown that treatment with a recombinant bacterial neuraminidase can promote the recovery of motor and autonomic function in a rat model of spinal cord contusion...